Veröffentlichungen in Fachzeitschriften

Bitte beachten Sie, dass alle Links dieser Seite auf externe Quellen (PubMed) verweisen und das MVZ München am Goetheplatz für die dort bereitgestellten Inhalte keine Verantwortung übernehmen kann.

2023

• Seroconversion rate of SARS-CoV-2 IgG antibodies and dating behaviour in HIV-PrEP users in a German metropolis during the COVID-19 pandemic.
  Weidlich S, Schneider J, Lee M, Mijočević H, Graf N, Protzer U, Spinner C, Noe S.
  Int J STD AIDS. 2023 Jul 17:9564624231190419. doi: 10.1177/09564624231190419.
• Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany.
  Schmidt D, Kollan C, Bartmeyer B, Bremer V, Schikowski T, Friebe M, Schellberg S, Scholten S, Bickel M, Hanhoff N, Rüsenberg R, Schewe K; NEPOS study group.Infection. 2023 Jun;51(3):665-678. doi: 10.1007/s15010-022-01919-3. Epub 2022 Sep 27
• Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
  Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, Porteiro N, Swindells S, Reynes J, Noe S, Harrington C, Español CM, Acuipil C, Aksar A, Wang Y, Ford SL, Crauwels H, van Eygen V, Van Solingen-Ristea R, Latham CL, Thiagarajah S, D’Amico R, Smith KY, Vandermeulen K, Spreen WR.
  Clin Infect Dis. 2023 May 3;76(9):1646-1654. doi: 10.1093/cid/ciad020
• Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany.
  Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, Krauss AS, Kolarikal H, Scholten S, Schuler C, Bickel M, Roll C, Kreckel P, Köppe S, Straub M, Klausen G, Lenz J, Esser S, Jensen B, Rausch M, Unger S, Pauli R, Härter G, Müller M, Masuhr A, Schäfer G, Seybold U, Schellberg S, Schneider J, Monin MB, Wolf E, Spinner CD, Boesecke C.
  HIV Med. 2023 Apr;24(4):389-397. doi: 10.1111/hiv.13378.
• Clinical and virological features of first human monkeypox cases in Germany.
  Noe S, Zange S, Seilmaier M, Antwerpen MH, Fenzl T, Schneider J, Spinner CD, Bugert JJ, Wendtner CM, Wölfel R.
  Infection. 2023 Feb;51(1):265-270. doi: 10.1007/s15010-022-01874-z. 

2022

• The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
  Alvarez E, Campbell L, Tinago W, Garcia-Leon A, Walsh I, Brady JJ, Burling K, Noe S, Neuville MF, Jouret F, Jamshidian F, Graham H, Rhee M, Mallon PW, Post FA.
  Antivir Ther. 2022 Aug;27(4):13596535221094898. doi: 10.1177/13596535221094898
• Monkeypox Virus Infection in Humans across 16 Countries – April-June 2022.
  Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen AE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM; SHARE-net Clinical Group.
  N Engl J Med. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323. Epub 2022 Jul 21.
• New reality in HIV therapy: Long-acting, injectable drugs.
  Oldenbuettel C, Wolf E. MMW Fortschr Med. 2022 Jun;164(Suppl 2):44-51. doi: 10.1007/s15006-022-1020-y.
• Inadequate PTH Response to Hypocalcemia in People Living with HIV.
  Noe S, Jonsson-Oldenbuettel C, Jaeger H, Schoenitzer V, Balogh A, Wolf E, ArcHiv Study Group.
  Curr HIV Res. 2022;20(3):200-203. doi: 10.2174/1570162X20666220322101839.

2021

• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
  Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W.
  Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0
• Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection.
  Postel N, Wolf E, Balogh A, Obermeier M, Degen O, Mayr C, Baumgarten A, Pauli R, Mueck B, Jaeger H, Noe S.
  Exp Clin Endocrinol Diabetes. 2021 Nov;129(11):798-802. doi: 10.1055/a-1210-2482. Epub 2021 Jan 21.
• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
  Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR.
  Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.
• Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
  Smith GHR, Henry WK, Podzamczer D, Masiá MDM, Bettacchi CJ, Arasteh K, Jaeger H, Khuong-Josses MA, Montes-Ramírez ML, Stellbrink HJ, Yazdanpanah Y, Richmond GJ, Sutton KC, Zhang F, McCoig CC, St Clair MH, Vandermeulen K, Van Solingen-Ristea R, Smith KY, Margolis DA, Spreen WR.
  Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439.
• Humoral response to SARS-CoV-2 vaccines in people living with HIV.
  Noe S, Ochana N, Wiese C, Schabaz F, Von Krosigk A, Heldwein S, Rasshofer R, Wolf E, Jonsson-Oldenbuettel C.
  Infection. 2022 Jun;50(3):617-623. doi: 10.1007/s15010-021-01721-7. Epub 2021 Oct 25.
• Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.
  Hoffmann C, Casado JL, Härter G, Vizcarra P, Moreno A, Cattaneo D, Meraviglia P, Spinner CD, Schabaz F, Grunwald S, Gervasoni C.HIV Med. 2021 May;22(5):372-378. doi: 10.1111/hiv.13037. Epub 2020 Dec 27.
• HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German ‚hotspot‘.
  Noe S, Schabaz F, Heldwein S, Mayer W, Ruecker K, Tiller FW, von Krosigk A, Wiese C, Balogh A, Gersbacher E, Jonsson-Oldenbuettel C, Jaeger H, Wolf E; ArcHIV study group.
  Infection. 2021 Apr;49(2):313-320. doi: 10.1007/s15010-020-01564-8. Epub 2021 Jan 2.

2020

• Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
  Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, Lombaard J, Katner H, Walmsley S, Khuong-Josses MA, Hudson K, Dorey D, Griffith S, Spreen W, Vanveggel S, Shaefer M, Margolis D, Chounta V.
  AIDS Behav. 2020 Dec;24(12):3533-3544. doi: 10.1007/s10461-020-02929-8.
• COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
  Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, Schabaz F, Gillor D, Postel N, Mueller MC, Müller M, Römer K, Schewe K, Hoffmann C.
• Future prospects of antiviral HIV therapy: what is in the pipeline?.
  Wolf E, Noe S.
  MMW Fortschr Med. 2020 Jun;162(Suppl 2):50-54. doi: 10.1007/s15006-020-0647-9.
• Not all is perfect with Tenofovir alafenamide.
  Noe S, Jonsson-Oldenbuettel C, Jaeger H.
  HIV Med. 2020 Jul;21(6):e10-e11. doi: 10.1111/hiv.12832. Epub 2019 Dec 29.
• Influence of antiretroviral therapy and cardiovascular disease on the immature platelet fraction in patients living with HIV.
  Goedel A, Müller S, Schwerdtfeger C, Zink A, Noe S, Bongiovanni D, Haller B, Spinner CD, Bernlochner I.
  Platelets. 2020 Aug 17;31(6):756-762. doi: 10.1080/09537104.2019.1678114. Epub 2019 Oct 13.
• High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study.
  Bickel M, Hoffmann C, Wolf E, Baumgarten A, Wyen C, Spinner CD, Jäger H, Postel N, Esser S, Mueller M, Stoehr A, Preis S, Klauke S, Schewe K; PROPHET study group of dagnae e.V..Infection. 2020 Jun;48(3):453-461. doi: 10.1007/s15010-020-01428-1. Epub 2020 May 11.

2019

• Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on „Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis“.
  Noe S, Jaeger H, Wolf E.
  Osteoporos Int. 2019 Aug;30(8):1705-1706. doi: 10.1007/s00198-019-05024-4. Epub 2019 May 29.
• Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
  Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, Canon V, Dorey D, Griffith S, Mrus J, Spreen W, Margolis D.
  HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):111-122. doi: 10.1080/25787489.2019.1661696.
• Safety analysis of German real-life cohort WIP shows rates of neuropsychiatric events leading to discontinuation of raltegravir therapy below 2.
  Naumann U, Moll A, Schleehauf D, Lutz KT, Schmidt W, Jaeger H, Funke B, Witte V.
  Int J STD AIDS. 2019 Jun;30(7):727-728. doi: 10.1177/0956462418812642.
• Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine – results from a German cohort study.
  Noe S, Heldwein S, Jaeger H, Page M, Wolf E.
  Int J STD AIDS. 2019 Apr;30(5):447-452. doi: 10.1177/0956462418815022. Epub 2019 Jan 10.

2018

• Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort.
  Noe S, Heldwein S, Wiese C, Pascucci R, von Krosigk A, Schabaz F, Jonsson-Oldenbuettel C, Jaeger H, Wolf E.
  Adv Pharmacol Sci. 2018 Dec 31;2018:6069131. doi: 10.1155/2018/6069131
• Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study.
  Noe S, Moeckel CI, Schwerdtfeger C, Oldenbuettel C, Jaeger H, Wolf E, Spinner CD.
  Interdiscip Perspect Infect Dis. 2018 Sep 2;2018:7502127. doi: 10.1155/2018/7502127
• Adrenal insufficiency due to ritonavir-triamcinolone drug-drug interaction without preceding Cushing’s syndrome.
  Noe S, Jaeger H, Heldwein S.
  Int J STD AIDS. 2018 Nov;29(11):1136-1139. doi: 10.1177/0956462418768689. Epub 2018 May 11.
• Anxiety, depression, and health-related quality of life in aging people living with HIV compared to diabetes patients and patients with minor health conditions: a longitudinal study.
  Ronel J, Dinkel A, Wolf E, Marten-Mittag B, Mueck B, Mayr C, Hoffmann C, Karwat M, Schewe K, Baumgarten A, Jaeger H.
  Psychol Health Med. 2018 Aug;23(7):823-830. doi: 10.1080/13548506.2018.1437276
• Prevalence of asymptomatic sexually transmitted infections in HIV-positive men who have sex with men in Germany: results of a multicentre cross-sectional study.
  Spinner CD, Boesecke C, Jordan C, Wyen C, Kümmerle T, Knecht G, Scholten S, Zink A, Krznaric I, Noe S.
  Infection. 2018 Jun;46(3):341-347. doi: 10.1007/s15010-018-1124-6. Epub 2018 Feb 19.
• Secondary Hyperparathyroidism in HIV-Infected Patients in Central Europe.
  Noe S, Oldenbuettel C, Heldwein S, Wiese C, von Krosigk A, Pascucci R, Ruecker K, Jaeger H, Wolf E.
  Horm Metab Res. 2018 Apr;50(4):317-324. doi: 10.1055/s-0043-125073. Epub 2018 Jan 23.
• Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
  Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK.HIV Med. 2018 Apr;19(4):299-307. doi: 10.1111/hiv.12579. Epub 2018 Jan 25.PMID: 29368456
• Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
  Grützner EM, Hoffmann T, Wolf E, Gersbacher E, Neizert A, Stirner R, Pauli R, Ulmer A, Brust J, Bogner JR, Jaeger H, Draenert R.
  Front Immunol. 2018 Apr 30;9:811. doi: 10.3389/fimmu.2018.00811.

2017

• Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study.
  Boretzki J, Wolf E, Wiese C, Noe S, Balogh A, Meurer A, Krznaric I, Zink A, Lersch C, Spinner CD.
  Patient Prefer Adherence. 2017 Nov 8;11:1897-1906. doi: 10.2147/PPA.S141762.
• Patterns of vitamin D, parathyroid hormone and c-terminal telopeptide of collagen type 1 in Caucasian and African descent HIV-infected populations in Central Europe.
  Noe S, Oldenbuettel C, Heldwein S, Jaeger H, Wolf E.
  Infect Dis Rep. 2017 Oct 2;9(3):7265. doi: 10.4081/idr.2017.7265
• Long-acting shot against HIV.
  Wolf E, Noe S.MMW Fortschr Med. 2017 Jun;159(Suppl 2):36-38. doi: 10.1007/s15006-017-9734-y.
• Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German ‚WIP‘ cohort.
  Naumann U, Moll A, Schleehauf D, Lutz T, Schmidt W, Jaeger H, Funke B, Witte V.
  Int J STD AIDS. 2017 Aug;28(9):893-901. doi: 10.1177/0956462416679550. Epub 2016 Nov 14.PMID: 28385065
• Cholecalciferol 20 000 IU Once Weekly in HIV-Positive Patients with Low Vitamin D Levels: Result from a Cohort Study.
  Noe S, Heldwein S, Pascucchi R, Oldenbüttel C, Wiese C, von Krosigk A, Jägel-Guedes E, Jäger H, Mayer W, Spinner CD, Wolf E.
  J Int Assoc Provid AIDS Care. 2017 Jul/Aug;16(4):315-320. doi: 10.1177/2325957417702487.
• Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
  Oldenbuettel C, Wolf E, Ritter A, Noe S, Heldwein S, Pascucci R, Wiese C, Von Krosigk A, Jaegel-Guedes E, Jaeger H, Balogh A, Koegl C, Spinner CD.
  Antivir Ther. 2017;22(2):169-172. doi: 10.3851/IMP3082. Epub 2016 Sep 2.

2016

• Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting.
  Schneider S, Spinner CD, Cassese S, Promny D, Hapfelmeier A, Byrne RA, Baumann M, Jäger H, Steinlechner E, Laugwitz KL, Kastrati A.
  AIDS. 2016 Jun 1;30(9):1413-21. doi: 10.1097/QAD.0000000000001063.
• Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.
  Spinner CD, Kern KE, Zink A, Wolf E, Balogh A, Noe S, Von Werder A, Schwerdtfeger C, Schmid RM, Iakoubov R.
  Antivir Ther. 2016;21(7):627-631. doi: 10.3851/IMP3049. Epub 2016 Apr 6.

2014

• 144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort.
  Wolf E, Trein A, Baumgarten A, Stephan C, Jaeger H, Hillenbrand H, Koeppe S, Lutz T, Koenig B, Stellbrink HJ.J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19770. doi: 10.7448/IAS.17.4.19770. eCollection 2014.PMID: 25397514

2013

• Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
  Harrer T, Plettenberg A, Arastéh K, Van Lunzen J, Fätkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G.Vaccine. 2014 May 7;32(22):2657-65. doi: 10.1016/j.vaccine.2013.10.030. Epub 2013 Oct 19.

Länger zurückliegende (Auswahl)

	Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H and the Prime-DAG and Ac-DAG Study Groups. Treatment during Primary HIV Infection Does Not Lower Viral Set Point but Improves CD4 Lymphocytes in an Observational Cohort. EurJMedRes 2009 Jul 22;14(7):277-83
	Jäger H, Wolf E. HIV-Eradikation – Fakten und Fiktion; Lässt sich das HI-Virus dauerhaft ausmerzen? MMW-Fortschritt Med. Sonderheft 1. 2008: 72-73
	Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A and PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6):568-79.
	Hill E, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E. Systematic review of clinical trials evaluating low doses of Stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007, 8 (5): 679-88
	Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, van Lunzen J, Stellbrink H-J, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst H-A. AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. Leukemia & Lymphoma. September 2006; 47(9):1872-1880
	Wolf E, Hoffmann C, Procaccianti M, Mosthaf F, Gersbacher E, Ulmer A, Karwat M, Brust J, Schuster D, Jaegel-Guedes E, Jaeger H. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. EurJMedRes. 2005; 10: 1-7
	*Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U. Cost effectiveness Analysis of Routine Use of Genotypic Resistance Testing after Failure of Antiretroviral Treatment for HIV. Antiviral Therapy. 2004 Feb., 9(1): 27-36
	*Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink H-J, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A, Wasmuth J-C, Rockstroh J, Mosthaf F, Horst H-A, Brodt H-R. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodkin’s disease. British Journal of Haematology. Vol. 125. Jan. 2004: 455-462
	Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoehr A, Plettenberg A, Stellbrink H-J, Jaeger H, Siebert U, Horst H-A. Response to Highly Active Antiretroviral Therapy Strongly Predicts Outcome in Patients with AIDS-Related Lymphoma. AIDS. 2003, 17: 1521-1529 *Abstracts. Nationale und internationale Kongresse
	(Auswahl)Koegl C, Baumgarten A, Bieniek B, Holm S, Hower M, Jaeger H, Lutz T, Mueller M, Schmidt W, Trein A, Pauli R, Wolf E, Petry R, Stellbrink HJ. Kivexa versus Truvada: Similar virological outcomes in ART-naive patients starting a Lopinavir/Ritonavir-based regimen. 48-week-data from the STAR and STELLA Cohorts. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19 – 22 July 2009.
	Abstract MOPEB055 (Poster)Wolf E, Stoll M, Becker-Andre M,. Bogner J, Becker W, Gorriahn D, Mueller MC, Jaeger H, Welte R, Baudewig M, Walli R. Prospective HLA-B*5701 screening for abacavir hypersensitivity saves costs. XVII International AIDS Conference, Mexico City, Mexico, August 03 – 08, 2008.
	Abstract THPE0192 (Poster)Stellbrink H-J, Schewe K, Hoffmann C, Wolf E. Is there a harmless level of plasma Viremia inuntreated HIV infection? CD4+ T Cells in the long-term follow-up of Elite Controllers and controls. 15th Conference on Retroviruses and Opportunistic Infections. Boston. 3.-6. Februar 2008. Abstract 351 (Poster)
	Koegl C, Wolf E, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, and the Prime-DAG and Ac-DAG Study Group. No Benefit from Early Treatment in Primary HIV-Infection? 14th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles. 25.- 28. February 2007. Late Breaker 125 (oral presentation)
	Wolf E, Koegl C, Theobald T, Jaegel-Guedes E, Jaeger H. Nevirapine-associated hepatotoxicity: no increased risk for females or high CD4 count in a single-centre HIV cohort. 46th annual ICAAC. San Francisco. 27.-30. September 2006. Abstract H-1063 (oral presentation)
	Wolf E, Gunturu G, Koegl C, Jaegel-Guedes E, Jaeger H. Tenofovir (TDF) versus non-TDF-containing ART: renal safety in daily practice. Eighth International Congress on Drug Therapy in HIV Infection. Glasgow. 12.-16. November 2006. Abstract P153 (Poster)
	Jaeger H, Wolf E, Jaegel-Guedes E, Chantratita W, Schumacher W. HIV real-time PCR assay COBAS AmpliPrep/COBAS TaqMan HIV-1 test in comparison to the Bayer bDNA assay versant HIV-1 RNA v3.0 and the Roche COBAS amplicor HIV monitor test v1.5. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract MOPE0156 (Poster)
	Wolf E, Walter H, Eckerlein B, Koegl C, Jaegel-Guedes E, Jaeger H. Development of De Novo PI-Resistance in Lopinavir/ Ritonavir-Monotherapy. 3rd IAS Conference on Pathogenesis and Treatment. Rio de Janeiro. 24.-27. Juli 2005. Abstract WePe4.4C08 (Poster)
	v. Krosigk A, Meyer T, Stoehr A, Jaegel-Guedes E, Jaeger H, Plettenberg A. Lymphograuloma venerum in HIV/AIDS: Increase in an often misdiagnosed disease. 10. Deutscher und 16. Österreichischer AIDS-Kongress. Wien. 1.-4. Juni 2005. Abstract V42 (oral presentation)
	Hill A, Ruxrungtham K, Havanich M, Wolf E, Milinkovich A, Gatell J, Ribera E. Meta-analysis of efficacy and safety for clinical studies of d4T 40mg versus 30mg BID in 1008 patients. XVI International AIDS Conference. Toronto. 13.-18. August 2006. Abstract THPE0120